1. Human papillomavirus antibody response following HAART initiation among MSM
- Author
-
Combes, Jean-Damien, Clifford, Gary M, Egger, Matthias, Cavassini, Matthias, Hirsch, Hans H, Hauser, Christoph, Calmy, Alexandra, Schmid, Patrick, Bernasconi, Enos, Günthard, Huldrych F, Franceschi, Silvia, Waterboer, Tim, Scherrer, Alexandra U, Swiss HIV Cohort, Study, University of Zurich, and Clifford, Gary M
- Subjects
Male ,HIV Infections ,Antibodies, Viral ,Viral/blood ,Anti-Retroviral Agents/therapeutic use ,Serology ,10234 Clinic for Infectious Diseases ,Switzerland/epidemiology ,Immune Reconstitution ,0302 clinical medicine ,Seroepidemiologic Studies ,immune system diseases ,Antiretroviral Therapy, Highly Active ,Immunology and Allergy ,Prospective Studies ,030212 general & internal medicine ,610 Medicine & health ,ddc:616 ,education.field_of_study ,Incidence (epidemiology) ,Papillomavirus Infections/epidemiology/immunology ,virus diseases ,Homosexuality ,Middle Aged ,female genital diseases and pregnancy complications ,Infectious Diseases ,Anti-Retroviral Agents ,030220 oncology & carcinogenesis ,2723 Immunology and Allergy ,360 Social problems & social services ,Switzerland ,Cohort study ,Adult ,medicine.medical_specialty ,Immunology ,Population ,HIV Infections/drug therapy ,Antiretroviral Therapy ,Antibodies ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Anal cancer ,Highly Active ,Homosexuality, Male ,Seroconversion ,education ,Aged ,2403 Immunology ,business.industry ,Papillomavirus Infections ,Cancer ,2725 Infectious Diseases ,medicine.disease ,Confidence interval ,Antibody Formation ,business - Abstract
OBJECTIVE To describe effects of HAART on high-risk human papillomavirus (HPV) antibody response in HIV-positive MSM and the meaning of this response for subsequent HPV-related cancer risk. DESIGN Prospective seroepidemiological study of 281 HIV-positive MSM initiating HAART between 1995 and 2004 in the Swiss HIV Cohort Study. METHODS For each individual, two serum samples, one at HAART initiation (pre-HAART) and another 24 months later (post-HAART), were tested for L1 antibodies to HPV6, 11, 16, 18, 31, 33, 35, 45, 52 and 58, as well as HPV16-E6 antibodies, using a multiplex serology assay. Identification of HPV-related cancer included data linkage with Swiss cancer registries. RESULTS Pre-HAART, 45.2% were seropositive for any high-risk HPV-L1 and 32.4% for HPV16-L1. Sexual intercourse during the last 6 months was the only evaluated factor associated with L1 seropositivity pre-HAART. Seropositivity increased post-HAART to 60.5% for any high-risk HPV-L1 [prevalence ratio versus pre-HAART = 1.34, 95% confidence interval (CI) 1.14-1.57] and 48.0% for HPV16-L1 (prevalence ratio versus pre-HAART = 1.48, 95% CI 1.20-1.83), and seroconversion was significantly associated with both lower CD4 cell count and CD4/CD8 ratio (P
- Published
- 2017